Human health is at the top of the agenda for Seattle-based tech innovators. Three companies in the biotech and healthcare space secured hefty funding rounds last year. Other industries including software and aerospace also saw significant investments. Read on to learn how these rounds could shape an upcoming year of growth for Seattle tech.
Largest Seattle Tech Funding Rounds in 2023
- Avalyn
- Stoke Space
- Viome
- Temporal
- DexCare
#4 (tied). $75 million, June 21
Backed by a total of $146 million in venture funding following its Series C round, DexCare plans to advance its platform. The company aims to extend healthcare access to everyone by matching patients with providers to extend limited health system capacity. DexCare’s solution serves more than 57 million patients in all 50 states.
#4 (tied). $75 million, February 28
Coding solution Temporal allows backend developers to incorporate durable execution into their software programs that help systems withstand failures more effectively. The company raised $75 million last year to grow its open-source product as well as its engineering and go-to-market teams.
#3. $86.5 million, August 18
Headquartered in Bellevue, Viome operates a healthtech platform that aims to redefine the aging process. The company secured a round of Series C capital to develop and expand its suite of personalized health tests. To date, the company has raised $175 million in venture funding.
#2. $100 million, October 5
Aerospace company Stoke Space wants to build reusable rockets and get them into orbit by 2025. It’s furthering its development program following a $100 million round of funding led by Industrious Ventures. The company plans to build its first-stage rocket engine and structure as well as the orbital version of its reusable second stage. The capital will also fuel the construction of Cape Canaveral Space Force Station’s Launch Complex 14.
#1. $175 million, September 27
Biopharma company Avalyn develops inhalation therapies to combat lung disease. The company pulled in an oversubscribed round of Series C funding from lead investors Perceptive Xontogeny Venture Funds, SR One and Eventide Asset Management. With its newest injection of capital, Avalyn plans to enter the next phases of developing its AP01 and AP02 therapies for interstitial lung disease.
